Developing tuberculosis vaccines for people with HIV: consensus statements from an international expert panel. Issue 11 (November 2022)

• Record Type: Journal Article
• Authors: Miner, Maurine D; Hatherill, Mark; Mave, Vidya; Gray, Glenda E; Nachman, Sharon; Read, Sarah W; White, Richard G; Hesseling, Anneke; Cobelens, Frank; Patel, Sheral; Frick, Mike; Bailey, Theodore; Seder, Robert; Flynn, Joanne; Rengarajan, Jyothi; Kaushal, Deepak; Hanekom, Willem; Schmidt, Alexander C; Scriba, Thomas J; Nemes, Elisa; Andersen-Nissen, Erica; Landay, Alan; Dorman, Susan E; Aldrovandi, Grace; Cranmer, Lisa M; Day, Cheryl L; Garcia-Basteiro, Alberto L; Fiore-Gartland, Andrew; Mogg, Robin; Kublin, James G; Gupta, Amita; Churchyard, Gavin;
• Is Part Of: Lancet. Volume 9:Issue 11(2022)
• Page Start: e791
• Page End: e800
• Publication Date: 2022-11
• Subjects: HIV (Viruses) -- Periodicals; HIV infections -- Periodicals; AIDS (Disease) -- Periodicals; 616.9792
• DOI: 10.1016/S2352-3018(22)00255-7
• Languages: English
• ISSNs: 2405-4704

Abstract

Summary: New tuberculosis vaccine candidates that are in the development pipeline need to be studied in people with HIV, who are at high risk of acquiring Mycobacterium tuberculosis infection and tuberculosis disease and tend to develop less robust vaccine-induced immune responses. To address the gaps in developing tuberculosis vaccines for people with HIV, a series of symposia was held that posed six framing questions to a panel of international experts: What is the use case or rationale for developing tuberculosis vaccines? What is the landscape of tuberculosis vaccines? Which vaccine candidates should be prioritised? What are the tuberculosis vaccine trial design considerations? What is the role of immunological correlates of protection? What are the gaps in preclinical models for studying tuberculosis vaccines? The international expert panel formulated consensus statements to each of the framing questions, with the intention of informing tuberculosis vaccine development and the prioritisation of clinical trials for inclusion of people with HIV.